If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the TRULICITY® (dulaglutide) formulation?
The formulation of Trulicity (dulaglutide) consists of dulaglutide 1.5 mg or dulaglutide 0.75 mg in a solution with several other components.
Dulaglutide is a clear, colorless, and sterile solution available as a
-
0.75 mg/0.5 mL solution in a single-dose pen
-
1.5 mg/0.5 mL solution in a single-dose pen
-
3 mg/0.5 mL solution in a single-dose pen, and
-
4.5 mg/0.5 mL solution in a single-dose pen.1
Each single-dose pen contains a 0.5-mL solution of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg of dulaglutide and excipients in water for injection that includes
-
0.07 mg citric acid anhydrous
-
23.2 mg mannitol, and
-
1.37 mg trisodium citrate dihydrate.1
Each-single dose pen also contains polysorbate 80 (0.10 mg for 0.75 mg and 1.5 mg; 0.125 mg for 3 mg and 4.5 mg).1
Enclosed Prescribing Information
TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly
1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Date of Last Review: August 24, 2020